Ketamine add-on for established status epilepticus treatment trial (KESETT) - the ketamine add-on therapy for established status epilepticus treatment trial (KESETT) is a phase III randomized,…

Active Cooperative Agreement Awarded

Award ID
UH3NS131532
Recipient
Awarding agency
Obligated
$5,668,197

Award facts

Completion date 5% complete
Place of performance
Charlottesville, VA, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded Cooperative Agreement UH3NS131532 to Rector & Visitors of the University of Virginia on September 4, 2026, obligating $5.668 million under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders. The award funds the Ketamine Add-on for Established Status Epilepticus Treatment Trial (KESETT), a Phase III, randomized, double-blind clinical trial. The trial tests whether ketamine at 1 or 3 mg/kg, added to levetiracetam at 60 mg/kg, is more effective than levetiracetam alone in treating status epilepticus after benzodiazepines have failed. The trial's proposed hypothesis is that adding ketamine raises efficacy from 47% to 62%. The period of performance runs from September 4, 2026 through August 31, 2030, and the place of performance is Charlottesville, VA, USA.

Description

Ketamine add-on for established status epilepticus treatment trial (KESETT) - the ketamine add-on therapy for established status epilepticus treatment trial (KESETT) is a phase III randomized, double-blind clinical trial to test whether ketamine (KET) (1 or 3 MG/KG) added to the standard therapy, levetiracetam (LEV), is more effective than levetiracetam (60 MG/KG) alone in treating status epilepticus after benzodiazepines have failed. Generalized convulsive status epilepticus (SE) is a dangerous but common neurologic emergency; IT can cause respiratory depression and permanent brain damage. Benzodiazepines are an effective first-line therapy, but approximately one-third of children and 40% of adults do not respond. Patients who fail benzodiazepines are in established status epilepticus. They are treated with second-line agents such as levetiracetam, which successfully terminates status epilepticus in only 47% of subjects. We propose that adding ketamine to levetiracetam will increase efficacy to 62%. Preclinical and clinical evidence supports this trial. Ketamine, an nmda receptor antagonist, terminates benzodiazepine refractory SE in experimental animals. Nmda receptor activation triggers self-reinforcing seizure mechanisms underlying SE. IT abrogates inhibitory plasticity, prevents excitotoxicity and neuronal death, and prevents epileptogenesis accompanying SE in experimental animals. Recent clinical studies in children and adults showed that ketamine terminated established status epilepticus in 23 of 24 subjects. Ketamine is used extensively in emergency settings for sedation, intubation, agitation, and pain management; IT is on the who essential medications list because IT is safely used extensively. Clinicians use IT effectively to treat refractory and super-refractory SE, and many experts recommend IT. ED physicians have used IT for decades for procedural sedation. We propose to test 1 and 3 MG/KG ketamine doses based on recent human studies, extensive pharmacokinetic modeling, animal-to-human dose conversion as suggested by the FDA, and data on the safety of ketamine. Our overall hypothesis is that ketamine added to LEV will improve the outcome of established status epilepticus compared to treatment with levetiracetam alone by clinically meaningful 15%. We will test this hypothesis by accomplishing the following specific aims in a bayesian-adaptive randomized clinical trial: aim 1: determine whether participants randomized to levetiracetam +3 MG/KG ketamine or levetiracetam +1 MG/KG ketamine will have more desirable outcomes than those receiving levetiracetam +placebo. We rank the outcomes on a scale ranging from 1 to 5. Aim 2: to ensure that the trial is informative for treating established status epilepticus in children by describing the effectiveness and rate of adverse reactions of these drugs. Aim 3: measure differences between treatment arms in secondary outcomes. This trial can change the treatment paradigm for SE by supplementing current second-line agents with ketamine to improve the timeliness of seizure termination.

Subawards

Subrecipient Amount Awarded
University Of California, Davis I. Background Information The objective of the project is to conduct a multicenter clinical trial to evaluate the efficacy of ketamine in the treatment of… $129,211
Regents Of The University Of Michigan Dr. Silbergleit is an Emergency Physician with expertise in the diagnosis and treatment of patients with refractory status epilepticus. He has considerable… $2,327,441
Children's Research Institute This subaward will support enrollment activities in the KESETT at Children’s National Hospital. Dr. Chamberlain and his team will perform start-up activities… $8,000

Quick answers

Who received award UH3NS131532?

UH3NS131532 was awarded to Rector & Visitors Of The University Of Virginia by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 4, 2026.

How much is award UH3NS131532 worth?

$5,668,197 has been obligated on UH3NS131532.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award